Camac Partners, ATG Capital Management Who Collectively Own Approximately 8.5% Stake In Forte Biosciences Have Filed A Definitive Proxy Statement In Connection With Forte's 2023 Annual Meeting Scheduled For September 19
Author: Benzinga Newsdesk | August 25, 2023 08:04am